Together, these results align with previous data, suggesting that elevated EZH2 may contribute to ferroptosis resistance by increasing SLC7A11 levels in MM, pointing to a therapeutic strategy combining EZH2 and ferroptosis targets. Here, SLC7A11 is linked to Miyoshi myopathy.